InsiderTrades

Form 4 for REGN Regeneron Pharmaceuticals

Accepted 2026-02-11 00:00:00 ET · period of report 2026-02-09 · accession 0001187443-26-000004 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
M 2026-02-11 2026-02-09 REGN RYAN ARTHUR F Dir S - Sale $778.53 -100 17.9K -0.6% -$77.9K

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-02-09 S D 5 $779.41 17,818 D — — (F5) Represents volume-weighted average price of sales of 5 shares of Company stock on February 9, 2026 at prices ranging from $779.13 to $779.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
2 Common Common Stock 2026-02-09 S D 1 $780.09 17,817 D — —
3 Common Common Stock 2026-02-09 S D 5 $781.48 17,812 D — — (F6) Represents volume-weighted average price of sales of 5 shares of Company stock on February 9, 2026 at prices ranging from $781.05 to $781.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
4 Common Common Stock 2026-02-09 S D 1 $782.53 17,811 D — —
5 Common Common Stock 2026-02-09 S D 3 $783.34 17,808 D — — (F7) Represents volume-weighted average price of sales of 3 shares of Company stock on February 9, 2026 at prices ranging from $783.20 to $783.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
6 Common Common Stock 2026-02-09 S D 1 $784.59 17,807 D — —
7 Common Common Stock 2026-02-09 S D 1 $785.71 17,806 D — —
8 Common Common Stock 2026-02-09 S D 2 $786.29 17,804 D — —
9 Common Common Stock 2026-02-09 S D 1 $787.82 17,803 D — —
10 Common Common Stock 2026-02-09 S D 12 $778.53 17,823 D — — (F4) Represents volume-weighted average price of sales of 12 shares of Company stock on February 9, 2026 at prices ranging from $778.11 to $778.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
11 Common Common Stock 2026-02-09 S D 57 $777.56 17,835 D — — (F3) Represents volume-weighted average price of sales of 57 shares of Company stock on February 9, 2026 at prices ranging from $777.02 to $777.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
12 Common Common Stock 2026-02-09 S D 1 $775.63 17,902 D — —
13 Common Common Stock 2026-02-09 S D 10 $776.59 17,892 D — — (F2) Represents volume-weighted average price of sales of 10 shares of Company stock on February 9, 2026 at prices ranging from $776.04 to $776.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.